S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
Log in

NASDAQ:VERUVeru Stock Price, Forecast & News

$2.95
+0.04 (+1.37 %)
(As of 07/15/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.89
Now: $2.95
$2.98
50-Day Range
$2.91
MA: $3.37
$3.74
52-Week Range
$1.67
Now: $2.95
$4.74
Volume449,800 shs
Average Volume497,031 shs
Market Capitalization$200.62 million
P/E RatioN/A
Dividend YieldN/A
Beta0.4
Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which is under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil and Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate. The company's oncology drug candidate includes VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-111, an oral alpha and beta tubulin inhibitor, which is under Phase 1b/2 study for the treatment of metastatic prostate, breast, endometrial, ovarian, and pancreatic cancers. It serves agencies, health care distributors, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Read More
Veru logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryPersonal Products
SectorMedical
Current SymbolNASDAQ:VERU
CUSIP31446210
Phone305-509-6897

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.80 million
Book Value$0.50 per share

Profitability

Net Income$-12,020,000.00

Miscellaneous

Employees171
Market Cap$200.62 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.

Veru (NASDAQ:VERU) Frequently Asked Questions

How has Veru's stock been impacted by COVID-19 (Coronavirus)?

Veru's stock was trading at $3.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VERU shares have decreased by 7.8% and is now trading at $2.95. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Veru?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veru.

When is Veru's next earnings date?

Veru is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Veru.

How were Veru's earnings last quarter?

Veru Inc (NASDAQ:VERU) released its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.03. The firm earned $9.94 million during the quarter, compared to the consensus estimate of $11.06 million. Veru had a negative return on equity of 31.14% and a negative net margin of 25.53%. View Veru's earnings history.

What price target have analysts set for VERU?

3 equities research analysts have issued 1-year price objectives for Veru's stock. Their forecasts range from $6.00 to $12.00. On average, they anticipate Veru's share price to reach $9.00 in the next year. This suggests a possible upside of 205.1% from the stock's current price. View analysts' price targets for Veru.

Has Veru been receiving favorable news coverage?

Media headlines about VERU stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Veru earned a daily sentiment score of -4.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the next several days. View the latest news about Veru.

Are investors shorting Veru?

Veru saw a increase in short interest in June. As of June 30th, there was short interest totaling 304,800 shares, an increase of 41.8% from the June 15th total of 215,000 shares. Based on an average trading volume of 427,600 shares, the short-interest ratio is presently 0.7 days. Currently, 0.6% of the shares of the company are sold short. View Veru's Current Options Chain.

Who are some of Veru's key competitors?

What other stocks do shareholders of Veru own?

Who are Veru's key executives?

Veru's management team includes the following people:
  • Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)
  • Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)
  • Mr. O. B. Parrish, Co-Founder & Director (Age 86)
  • Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)
  • Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51)

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

Who are Veru's major shareholders?

Veru's stock is owned by many different institutional and retail investors. Top institutional investors include Wedge Capital Management L L P NC (0.43%). Company insiders that own Veru stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View institutional ownership trends for Veru.

Which institutional investors are selling Veru stock?

VERU stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. View insider buying and selling activity for Veru.

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $2.95.

How big of a company is Veru?

Veru has a market capitalization of $200.62 million and generates $31.80 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Veru employs 171 workers across the globe.

What is Veru's official website?

The official website for Veru is www.veruhealthcare.com.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.